Home » News » Product updates

Product updates

Targin – New 60/30mg and 80/40mg Strengths

Mundipharma Pharmaceuticals Ltd is pleased to announce the launch of Targin 60/30mg and 80/40mg prolonged-release tablets (60/30mg and 80/40mg oxycodone/naloxone). Targin contains the opioid analgesic oxycodone and is indicated for the treatment of severe pain, which can be adequately managed only with opioid analgesics. A recognised side-effect of opioid treatment is opioid-induced constipation (OIC). The severity of OIC experienced can ...

Symbicort Turbohaler – Expanded Indication for Asthma in Adolescents

AstraZeneca Pharmaceuticals (Ireland) DAC is pleased to announce that Symbicort Turbohaler (budesonide/ formoterol fumarate dihydrate) inhalation powder in 100/6mcg & 200/6mcg strengths have received approval for use as maintenance and reliever therapy for asthma in adolescents (aged 12 to 17 years). Budesonide/ formoterol fumarate dihydrate is a combination corticosteroid/ selective long acting b2-agonist. The 100/6mcg strength is already approved for ...

Hay Fever Policy (Glucocorticoid Injections)

Therapeutic Use Exemption (TUE) Committee Policy on Glucocorticoid Injections for Hay Fever Depo-Medrone (Methylprednisolone) and Kenalog* (Triamcinolone) administered by intra-muscular injection as treatment for hay fever are prohibited in sport and therefore their use requires the athlete and their physician to strictly adhere to the TUE Policy. The TUE Policy is available at www.sportireland.ie/Anti-Doping/Athlete-Zone/Therapeutic-Use-Exemptions-/ Athletes included in their International Federation ...

Pradaxa – Capsule Colour Change

Boehringer Ingelheim Ltd wish to announce a colour change for Pradaxa (dabigatran etexilate) 75mg, 110mg and 150mg hard capsules. The capsules are now white, light blue and light blue/white, respectively, and are all marked with R, their strength and the Boehringer Ingelheim company symbol. This colour change does not impact the efficacy and safety profile of dabigatran. The change is ...

Violite – Now Available on GMS Reimbursement Scheme

Consilient Health Ireland are delighted to announce that Violite (levonorgestrel/ ethinylestradiol 100/20mcg) is now available on the GMS reimbursement scheme from 1st April 2017. It is reimbursed at €6.07 for a three month supply of film-coated tablets (3 x 21, €5.62 Price To Wholesalers). Violite is a combined oral contraceptive pill and is indicated for the prevention of pregnancy. The ...

Flolan – New sterile solvent with different pH

GlaxoSmithKline is pleased to announce the launch of a new formulation of Flolan (epoprostenol) solution for infusion. The new more thermostable formulation eliminates the need for use of a cold pouch/ice pack during administration and will be introduced to the Irish market on 20th March 2017. New storage and administration conditions when using the new formulation (with solvent pH 12): ...

Azalia – Now Available on GMS Reimbursement Scheme

Consilient Health Ireland is delighted to announce that Azalia (desogestrel 75mcg) is now available on the GMS reimbursement scheme from 1st January 2017. It will be reimbursed at €7.47 for a three month supply of film-coated tablets (3 x 28, €6.92 Price To Wholesalers). Azalia is a progestogen-only contraceptive pill and is indicated for the prevention of pregnancy in women ...

Bufomix Easyhaler – New 80/4.5mcg Strength

Orion Pharma Ireland is pleased to announce the addition of Bufomix Easyhaler 80/4.5mcg to its current portfolio. It is now available with the complete range of strengths and license indication of the original brand. Bufomix Easyhaler is a fixed-dose budesonide/formoterol combination inhaler, indicated for the treatment of asthma and chronic obstructive pulmonary disease. Three strengths are now available; – New: ...

Attitudes and Understanding of Cancer Clinical Trials among People with Cancer the Focus of National Study about to be Launched

Details of a new national study ‘Understanding and Attitudes toward Cancer Clinical Research (CCR) among Patients with a Cancer Diagnosis’ were announced on Monday 18th April 2016. The study aims to increase participation rates in Ireland to clinical trials by increasing patients’ understanding of cancer clinical trials. The research is being conducted by All Ireland Cooperative Oncology Research Group (ICORG), ...